Navigation Links
20th ECNP Congress 2007, Oct. 13-17, Vienna, Austria
Date:10/4/2007

Mental disorders are major causes of disability worldwide and rank as number one in terms of direct and indirect health economic costs as a recent ECNP commissioned report has demonstrated (Wittchen et al 2005). Depression, for instance, produces the greatest decrement in health compared with the common chronic diseases angina pectoris, arthritis, asthma, and diabetes (Moussavi et al., 2007) followed by addictive disorders (nicotine, alcohol, drugs). Unmet needs for mental health treatment today are pervasive all over the world and especially concerning in less-developed countries. A recent large worldwide study with 84.850 adults living in 17 low- to middle-income and high-income countries points out that although up to 30% of the population is expected to have clear-cut mental illness every year, in every one country studied, at least two-thirds of people who are mentally ill receive no treatment. In Europe, 27% of the population is affected by mental illness every year, but 74% is not treated, whereas only 8% of diabetics receives no care (Wittchen & Jacobi 2005; Wang et al., 2007; Thornicroft 2007). Thus, there is a compelling need to improve the fate of people struck by mental disorders, and vigorously reinforce the value of psychiatry and related disciplines for society.

20th ECNP Congress, Vienna

This week (13-17 October 2007) over 6000 psychiatrists, neurologists, psychologists and neuroscience researchers and practitioners from all over the world will join in Vienna at the 20th ECNP Congress to present and discuss the latest breakthroughs, the progress and the future perspectives in the fields of the origin and treatment of mental disorders, disorders of the brain, neuropsychopharmacology and related fields.

This largest high scientific standard meeting in Europe will provide all participants with the latest achievements and future perspectives in neuropsychopharmacology and closely related fields of virtually all disorde
'/>"/>

Contact: Sonja Mak
s.mak@update.europe.at
43-140-557-3413
European College of Neuropsychopharmacology
Source:Eurekalert

1

GOOD

Page: 1 2 3 4

Related biology news :

1. New results validating Pall prion reduction filter disclosed at ISBT Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
(Date:12/3/2009)The UK leads the world when it comes to investment in energy efficient technologies research, but Engineering and Physical Sciences Research Council (EPSRC) Chief Executive Dave Delpy believes that mo
(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O
Breaking Biology News(10 mins):Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Research is vital to a cleaner, greener, low carbon future 2CCNY professor foresees rising Antarctic snowmelt 2Special Needs Equipment Rentals Save the Day for Travelers with Physical Disabilities 55997 1Special Needs Equipment Rentals Save the Day for Travelers with Physical Disabilities 55997 2Special Needs Equipment Rentals Save the Day for Travelers with Physical Disabilities 55997 3MarketsandMarkets 3A Global Emerging Lighting Technologies Market Worth US 24112 2 Billion by 2014 55993 1MarketsandMarkets 3A Global Emerging Lighting Technologies Market Worth US 24112 2 Billion by 2014 55993 2MarketsandMarkets 3A Global Emerging Lighting Technologies Market Worth US 24112 2 Billion by 2014 55993 3Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 55989 1Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 55989 2Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 55989 3Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 55989 4
(Date:12/4/2009)NEW YORK, Dec. 4 Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chroni
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at a conference on Hig
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
Breaking Biology Technology:Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9
X-GAL (5-Bromo-4-Chloro-3-Indolyl-Beta-D-Galactopyranoside), = 99.0% from AMRESCO, Inc.
Custom Peptide Synthesis from Raybiotech, Inc.
DTNB from Cayman Chemical
Keyhole Limpet Hemocyanin NP-KLH (Keyhole Limpet Hemocyanin), Unconjugated from Biosearch Technologies
Biology Products: